Selumetinib Disease Interactions
There are 2 disease interactions with selumetinib.
Selumetinib (applies to selumetinib) cardiomyopathy
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease
Cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF) >=10% below baseline, occurred in over 20% of pediatric patients who received selumetinib. The safety of this drug has not been established in patients with a history of impaired LVEF or an ejection fraction below the limit of normal. Caution is advised if using on these patients. Assess ejection fraction by echocardiogram prior to initiating treatment, and periodically during therapy.
References (1)
- (2020) "Product Information. Koselugo (selumetinib)." Astra-Zeneca Pharmaceuticals
Selumetinib (applies to selumetinib) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Selumetinib exposure is increased in patients with moderate or severe hepatic impairment. A recommended dosage has not been established for patients with severe hepatic impairment (Child-Pugh C), and a dose reduction is required in patients with moderate hepatic impairment (Child-Pugh B). Caution is advised when using in patients with these levels of hepatic impairment.
References (1)
- (2020) "Product Information. Koselugo (selumetinib)." Astra-Zeneca Pharmaceuticals
Switch to consumer interaction data
Selumetinib drug interactions
There are 262 drug interactions with selumetinib.
Selumetinib alcohol/food interactions
There is 1 alcohol/food interaction with selumetinib.
Report options
More about selumetinib
- selumetinib consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Koselugo
Koselugo is used to treat neurofibromatosis type 1 (NF1) in children aged 2 years and older who ...
Mirdametinib
Mirdametinib (Gomekli) is a treatment for neurofibromatosis type 1 with plexiform neurofibromas ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
